- Home
- DOUG vs GLSI Comparison
DOUG vs GLSI Comparison
Compare DOUG & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- GLSI
- Stock Information
- Founded
- DOUG 1911
- GLSI 2006
- Country
- DOUG United States
- GLSI United States
- Employees
- DOUG N/A
- GLSI N/A
- Industry
- DOUG Building operators
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- GLSI Health Care
- Exchange
- DOUG Nasdaq
- GLSI Nasdaq
- Market Cap
- DOUG 161.5M
- GLSI 133.4M
- IPO Year
- DOUG N/A
- GLSI 2020
- Fundamental
- Price
- DOUG $2.31
- GLSI $10.03
- Analyst Decision
- DOUG
- GLSI Strong Buy
- Analyst Count
- DOUG 0
- GLSI 1
- Target Price
- DOUG N/A
- GLSI $39.00
- AVG Volume (30 Days)
- DOUG 1.0M
- GLSI 39.7K
- Earning Date
- DOUG 08-06-2025
- GLSI 08-13-2025
- Dividend Yield
- DOUG N/A
- GLSI N/A
- EPS Growth
- DOUG N/A
- GLSI N/A
- EPS
- DOUG N/A
- GLSI N/A
- Revenue
- DOUG $1,048,791,000.00
- GLSI N/A
- Revenue This Year
- DOUG $17.61
- GLSI N/A
- Revenue Next Year
- DOUG N/A
- GLSI N/A
- P/E Ratio
- DOUG N/A
- GLSI N/A
- Revenue Growth
- DOUG 11.36
- GLSI N/A
- 52 Week Low
- DOUG $1.03
- GLSI $8.06
- 52 Week High
- DOUG $3.20
- GLSI $17.49
- Technical
- Relative Strength Index (RSI)
- DOUG 45.13
- GLSI 63.80
- Support Level
- DOUG $2.27
- GLSI $8.97
- Resistance Level
- DOUG $2.46
- GLSI $9.19
- Average True Range (ATR)
- DOUG 0.13
- GLSI 0.37
- MACD
- DOUG -0.06
- GLSI 0.11
- Stochastic Oscillator
- DOUG 15.80
- GLSI 87.11
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.